Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- FRONTIERS IN IMMUNOLOGY10 · 2019
- 피인용
- Web of Science 24Scopus 24
- FWCI (Scopus)
- 0.82
- JCR IF
- JCR 2018 4.716
- ISSN
- 1664-3224
저자
- 박규태제1저자Department of Physiology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 권양우Department of Physiology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 이태욱Department of Physiology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 권성규Department of Physiology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 고현창Department of Dermatology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 김문범Department of Dermatology, Pusan National University School of Medicine, Yangsan-si, South Korea
- 김재호교신저자Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan-si, South Korea
초록
Systemic sclerosis is a profibrotic autoimmune disease mediated by the dysregulation of extracellular matrix synthesis. Formyl peptide receptor 2 (Fpr2) is a G protein-coupled receptor that modulates inflammation and host defense by regulating the activation of inflammatory cells, such as macrophages. However, the role of Fpr2 in the development and therapy of scleroderma is still unclear. The present study was conducted to investigate the effects of Fpr2 activation in the treatment of scleroderma fibrosis. We found that intradermal administration of WKYMVm, an Fpr2-specific agonist, alleviated bleomycin-induced scleroderma fibrosis in mice and decreased dermal thickness in scleroderma skin. WKYMVm-treated scleroderma skin tissues displayed reduced numbers of myofibroblasts expressing a-smooth muscle actin, Vimentin, and phosphorylated SMAD3. WKYMVm treatment attenuated macrophage infiltration in scleroderma skin and reduced the number of M2 macrophages. The therapeutic effects of WKYMVm in scleroderma-associated fibrosis and inflammation were completely abrogated in Fpr2 knockout mice. Moreover, WKYMVm treatment reduced the serum levels of inflammatory cytokines, such as tumor necrosis factor-alpha, and interferon-gamma, in the scleroderma model of wild-type mice but not in Fpr2 knockout mice. These results suggest that WKYMVm-induced activation of Fpr2 leads to alleviation of fibrosis by stimulating immune resolution in systemic sclerosis.
키워드
systemic sclerosissclerodermafibrosisFpr2WKYMVmSKIN FIBROSISLIPOXIN A(4)FIBROBLASTSMECHANISMSEXPRESSIONIMMUNEMACROPHAGESINHIBITIONRESPONSESCXCR4
식별자
- Scopus EID
- 2-s2.0-85072604233
- WoS UID
- 000483540600002



로그인
연구물 목록으로